Hogan Lovells US LLP

Hogan Lovells US LLP fields a deep litigation bench with expertise in the life sciences, strengthened by the October 2023 arrivals from Dechert LLP of patent litigators Howard Levine in Washington DC and Jennifer Swan in Silicon Valley, both of whom have experience in Hatch-Waxman disputes. On the non-contentious front, the practice supports major players in the pharmaceutical sector with their patent protection strategies, and is also noted for its work navigating the FDA approvals process. Leadership of the overarching practice is split between Philadelphia-based Steve Abrams, who handles IPOs and M&As in the sector, and Washington DC’s Lynn Mehler, who guides drug and biologics developers through the FDA approvals process; FDA approvals are also the key area of focus for Randy Prebula, also based in the capital. In Denver, Jodi Scott advises medical device manufacturers on MDRs and FDA inspections, while Washington’s David Fox tackles Hatch-Waxman litigation as it relates to generic drug production. Product liability litigation is the domain of Baltimore’s Lauren Colton, who represents clients facing MDLs and class actions, while Cullen Taylor and Anishiya Abrol, based in Virginia and Washington respectively, as supporting clients with the protection of their drug and medical devices patent portfolios and licensing transactions. Houston’s Andrew Strong is well versed in assisting early stage companies with growth strategies, financing and mergers.